Puma Biotechnology vs UroGen Pharma
PBYI and URGN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PBYI and URGN compare
UroGen Pharma is the larger company, worth 4.0 times as much as Puma Biotechnology ($1.5B against $369M).
UroGen Pharma grew revenue faster over the last twelve months (100% versus −2.9% for Puma Biotechnology).
Puma Biotechnology keeps more of each dollar of sales as profit, with a net margin of 11.6% compared with −51.7% at UroGen Pharma.
Puma Biotechnology scores higher on the StockData Score (14 against 6 for UroGen Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PBYI | URGN |
|---|---|---|
| Size and price | ||
| Market cap | $369M | $1.5B |
| Share price | $7.14 | $29.87 |
| Change, 1 year | 46.0% | 25.7% |
| Change, 5 years | 121% | 146% |
| Beta (5Y) | 1.32 | 2.73 |
| Employees | 179 | 291 |
| StockData Score | ||
| Total score | 14 (better) | 6 |
| Valuation score | 2 (better) | 0 |
| Growth score | 2 | 3 (better) |
| Performance score | 5 (better) | 2 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 13.7× | – |
| P/S | 1.6× (better) | 7.7× |
| P/B | 2.7× | – |
| EV/EBITDA | 6.9× | – |
| P/FCF | 9.0× | – |
| FCF yield | 11.2% (better) | −10.9% |
| Fair value | $8.84 | – |
| Margin of safety | 19.2% | – |
| Growth | ||
| Revenue growth (TTM) | −2.9% | 100% (better) |
| Revenue growth, 5Y average | 0.29% | 56.2% (better) |
| Net income growth (TTM) | −44.9% | – |
| EPS growth (TTM) | −46.9% | – |
| Profitability | ||
| Gross margin | 74.8% | 90.8% (better) |
| Operating margin | 13.2% (better) | −35.3% |
| Net margin | 11.6% (better) | −51.7% |
| FCF margin | 17.8% (better) | −84.3% |
| Return on equity | 22.0% | – |
| Return on invested capital | 42.7% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Net debt / EBITDA | −2.12 | – |
| Interest coverage | 8.6× | – |
| Current ratio | 2.91 | 3.80 (better) |
| Altman Z-score | −2.90 | −2.55 (better) |
| Piotroski F-score | 8 (better) | 0 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 74.9% | 86.8% |
| Held by insiders | 18.9% | 5.6% |
| Insider net buying, 12 months | −$2.1M (better) | −$4.5M |
| Short interest, % of float | 10.3% | 11.1% |
Go deeper
- PBYI stock overview
- PBYI income statement
- PBYI valuation and score
- URGN stock overview
- URGN income statement
- URGN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.